Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ProQR (DE:0PQ)
BERLIN:0PQ
ProQR (0PQ) Stock Price & Analysis
1 Followers
0PQ Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.07 - €2.56
Previous Close€1.8
Volume0.00
Average Volume (3M)662.00
Market Cap
€146.49M
Enterprise Value€30.90M
Total Cash (Recent Filing)€118.92M
Total Debt (Recent Filing)€19.73M
Price to Earnings (P/E)N/A
Beta0.10
Next Earnings
May 09, 2024EPS Estimate
-€0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding81,354,592
10 Day Avg. Volume0
30 Day Avg. Volume662
Standard Deviation0.23
R-Squared0.10
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)3.87
Price to Sales (P/S)28.70
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.41Price Target Upside89.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
ProQR News
PremiumCompany Announcements
ProQR Therapeutics Announces Board Nomination and AGM
PremiumCompany Announcements
ProQR Solidifies Lead in RNA Therapy Innovation
Bulls Say, Bears Say
Bulls Say
Strategic CollaborationsCollaboration with Eli Lilly and the Rett Syndrome Research Trust may lead to further advancements and financial benefits, positioning the company for potential success.
Technology ValidationEditing profiles in iPSC derived neurons and cerebral organoids further validate the partnership with the Rett Syndrome Research Trust, highlighting the platform's versatility.
Therapeutic PotentialAxiomer platform’s potential to target CNS diseases looks promising, offering a new avenue for treating these challenging conditions.
Bears Say
Clinical DataThe lower GalNAc editing in mice for PRQR’s candidate fell below the target range and what competitors like Korro have reported, potentially raising concerns about its efficacy.
Competitive PositionPRQR's recent data presentation suggests it may be lagging behind competitors in editing efficiency, which could impact investor confidence and the stock's value.
Stock PerformancePRQR shares were down after the presentation, which may be attributed to editing efficiency issues.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
6.84% Other Institutional Investors
93.16% Public Companies and
Individual Investors
0PQ FAQ
What was ProQR’s price range in the past 12 months?
ProQR lowest stock price was €1.06 and its highest was €2.56 in the past 12 months.
What is ProQR’s market cap?
Currently, no data Available
When is ProQR’s upcoming earnings report date?
ProQR’s upcoming earnings report date is May 09, 2024 which is in 6 days.
How were ProQR’s earnings last quarter?
ProQR released its earnings results on Mar 13, 2024. The company reported -€0.07 earnings per share for the quarter, missing the consensus estimate of €0.017 by -€0.087.
Is ProQR overvalued?
According to Wall Street analysts ProQR’s price is currently Undervalued.
Does ProQR pay dividends?
ProQR does not currently pay dividends.
What is ProQR’s EPS estimate?
ProQR’s EPS estimate is -€0.11.
How many shares outstanding does ProQR have?
Currently, no data Available
What happened to ProQR’s price movement after its last earnings report?
ProQR reported an EPS of -€0.07 in its last earnings report, missing expectations of €0.017. Following the earnings report the stock price went up 0.933%.
Which hedge fund is a major shareholder of ProQR?
Among the largest hedge funds holding ProQR’s share is Gilder Gagnon Howe & Co LLC.. It holds ProQR’s shares valued at N/A.
---
ProQR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€3.41 (89.07% Upside)
€3.41 (89.07% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.00%
12-Months-Change
Fundamentals
Return on Equity
-52.57%
Trailing 12-Months
Asset Growth
-16.70%
Trailing 12-Months
Company Description
ProQR
ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.
---
0PQ Stock 12 Months Forecast
Average Price Target
€3.41
▲(89.07% Upside)
Technical Analysis
Best Analysts Covering 0PQ
1 Year
1 Year Success Rate
9/21 ratings generated profit
1 Year Average Return
-19.35%
reiterated a buy rating 2 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -19.35% per trade.
---